Analyst Price Targets — CSLLY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 9, 2022 7:01 pm | Chris Cooper | Goldman Sachs | $307.00 | $102.97 | TheFly | CSL reinstated with a Neutral at Goldman Sachs |
Latest News for CSLLY
Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co , granting it certain rights to develop and commercialise clazakizumab, an antibody aimed at preventing heart-related illness and death in people with end‑stage kidney disease.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
After losing some value lately, a hammer chart pattern has been formed for CSL Limited (CSLLY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CSL Limited (CSLLY) Q2 2026 Earnings Call Transcript
CSL Limited (CSLLY) Discusses Leadership Transition and Appointment of Interim CEO Transcript
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CSLLY.
Senate Trading
No Senate trades found for CSLLY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.